Pre-clinical testing from a top preclinical CRO in Eastern Europe.
We are an independent CRO based in the USA that conducts preclinical drug testing in top-notch, GLP-certified research facilities in Kiev, Ukraine. Our testing sites are supported by the UNAMS and Ministry of Health and offer support for for-profit development of new medicine discoveries as part of their core purpose. Our business was created to offer the top-notch, inexpensive services of these research sites to emerging bio-tech companies in the USA and Europe, thereby providing them with an attractive option for promoting development programs quickly and at much lower cost than other commercial Contract Research Organizations. We provide a broad range of preclinical Contract Research Organization including drug safety, chronic and acute toxicity, pharmacological screening, bioavailability, bio-equivalence , and complete in vitro and in vivo screening for anticancer activity.
Our preclinical CRO is able to price pre-clinical research far below other CROs since we have a very low overhead in the United States and perform all trials in Ukraine where personnel and facility costs are much lower. Our team in the U.S. is comprised of only of the organization principals who deal directly with customers; we don’t have any marketing costs aside from our site, and no head offices, supporting staff or other overhead to inflate prices. We have much lower research conduct prices in Kiev, UA due to much lower workers rates and are able to offer our most attractive rates for longer and more intricate preclinical studies where labor is the most significant portion of the overall cost. Because we utilize the same stable international suppliers for animal models, reagents and laboratory supplies as other CROs, we don’t have any cost savings on these materials and thus less overall cost advantage for very short-term pre-clinical trials. However, regardless of your test protocol and length, our goal is to provide our customers the greatest possible value for their investment.